*
Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, Lee SK, Lee YC, Kim HR, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC.
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
Oncotarget 6:2562-72, 2015
*
Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, Kim HR, Moon YW, Kim HS, Cho BC, Shim HS.
The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lungcancer.
Lung Cancer 88: 325-331, 2015
*
Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, Kim B, Steeg PS, Sarfaraz S, Changwoo Lee L, Voeller D, Choi EY, Luo J, Palmieri D, Chung HC, Kim JH, Wang Y, Giaccone G.
LAMC2 enhances the metastatic potential of lung adenocarcinoma.
Cell Death Diff 22:1341-1352, 2015
*
Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC.
Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma.
Mol Cancer Ther pii: molcanther.0350.2015 (epub)
*
Moon YW, Hajjar J, Hwu P, Naing A.
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
J Immunother Cancer 3:51, 2015
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Oncotarget 6: 44971-84; 2015